Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 84Carcinoma, Non-Small-Cell Lung 56Triple Negative Breast Neoplasms 35Breast Neoplasms 34Neoplasms 28Neoplasm Metastasis 28Colorectal Neoplasms 17Lung Neoplasms 13Carcinoma, Pancreatic Ductal 10Parkinson Disease 4, Autosomal Dominant Lewy Body 9Adenocarcinoma 9Stomach Neoplasms 8Melanoma 8Carcinoma 8Ovarian Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Neoplasms by Site 6Fallopian Tube Neoplasms 6Small Cell Lung Carcinoma 5Carcinoma, Squamous Cell 5Peritoneal Neoplasms 4Head and Neck Neoplasms 4Digestive System Neoplasms 4Carcinoma, Transitional Cell 4Urinary Bladder Neoplasms 3Solid Tumor 3Sarcoma 3Rectal Neoplasms 3Pancreatic Diseases 3Neoplasms by Histologic Type 3

Interventions

Cisplatin 3pembrolizumab 2bintrafusp alfa protein, human 2Gemcitabine 2vactosertib 1enzalutamide 1Trabedersen 1Temozolomide 1Sorafenib 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Paclitaxel 1Lomustine 1LY3300054 1LY-2157299 1Drug Delivery Systems 1Carboplatin 1Bevacizumab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Camurati-Engelmann Syndrome × 130-nm albumin-bound paclitaxel × Clear all
NCT02937272 2026-04-03

A Study of LY3200882 in Participants With Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
223 enrolled

Camurati-Engelmann Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡